These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 19051820)

  • 1. Comorbidity and age affect treatment policy for cervical cancer: a population-based study in the south of The Netherlands, 1995-2004.
    van der Aa MA; Siesling S; Kruitwagen RF; Lybeert ML; Coebergh JW; Janssen-Heijnen ML
    Eur J Gynaecol Oncol; 2008; 29(5):493-8. PubMed ID: 19051820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age-specific differences in the treatment of cervical cancer in the east and the south of The Netherlands 1989-2004.
    van der Aa MA; Siesling S; v d Poll-Franse LV; Schutter EM; Lybeert ML; Coebergh JW
    Eur J Obstet Gynecol Reprod Biol; 2009 Nov; 147(1):78-82. PubMed ID: 19713027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age-specific differences in treatment and survival of patients with cervical cancer in the southeast of The Netherlands, 1986-1996.
    de Rijke JM; van der Putten HW; Lutgens LC; Voogd AC; Kruitwagen RF; van Dijck JA; Schouten LJ
    Eur J Cancer; 2002 Oct; 38(15):2041-7. PubMed ID: 12376210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increasing age predicts poor cervical cancer prognosis with subsequent effect on treatment and overall survival.
    Quinn BA; Deng X; Colton A; Bandyopadhyay D; Carter JS; Fields EC
    Brachytherapy; 2019; 18(1):29-37. PubMed ID: 30361045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High dose-rate brachytherapy for elderly patients with uterine cervical cancer.
    Chen SW; Liang JA; Yang SN; Lin FJ
    Jpn J Clin Oncol; 2003 May; 33(5):221-8. PubMed ID: 12865465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of nedaplatin-based concurrent chemoradiotherapy for FIGO Stage IB2-IVA cervical cancer and its clinical prognostic factors.
    Fujiwara M; Isohashi F; Mabuchi S; Yoshioka Y; Seo Y; Suzuki O; Sumida I; Hayashi K; Kimura T; Ogawa K
    J Radiat Res; 2015 Mar; 56(2):305-14. PubMed ID: 25428244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors in definitive radiotherapy of uterine cervical cancer.
    Yalman D; Aras AB; Ozkök S; Duransoy A; Celik OK; Ozsaran Z; Haydaroğlu A
    Eur J Gynaecol Oncol; 2003; 24(3-4):309-14. PubMed ID: 12807246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is the revised 2018 FIGO staging system for cervical cancer more prognostic than the 2009 FIGO staging system for women previously staged as IB disease?
    Ayhan A; Aslan K; Bulut AN; Akilli H; Öz M; Haberal A; Meydanli MM
    Eur J Obstet Gynecol Reprod Biol; 2019 Sep; 240():209-214. PubMed ID: 31325847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The adverse effect of treatment prolongation in cervical cancer by high-dose-rate intracavitary brachytherapy.
    Chen SW; Liang JA; Yang SN; Ko HL; Lin FJ
    Radiother Oncol; 2003 Apr; 67(1):69-76. PubMed ID: 12758242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors in FIGO stage IB-IIA small cell neuroendocrine carcinoma of the uterine cervix treated surgically: results of a multi-center retrospective Korean study.
    Lee JM; Lee KB; Nam JH; Ryu SY; Bae DS; Park JT; Kim SC; Cha SD; Kim KR; Song SY; Kang SB
    Ann Oncol; 2008 Feb; 19(2):321-6. PubMed ID: 17962205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Operable Stages IB and II cervical carcinomas: a retrospective study comparing preoperative uterovaginal brachytherapy and postoperative radiotherapy.
    Atlan D; Touboul E; Deniaud-Alexandre E; Lefranc JP; Antoine JM; Jannet D; Lhuillier P; Uzan M; Huart J; Genestie C; Antoine M; Jamali M; Ganansia V; Milliez J; Uzan S; Blondon J
    Int J Radiat Oncol Biol Phys; 2002 Nov; 54(3):780-93. PubMed ID: 12377330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathological variables predictive of clinical outcome in patients with FIGO stage Ib2-IIb cervical cancer treated with cisplatin-based neoadjuvant chemotherapy followed by radical hysterectomy.
    Gadducci A; Teti G; Barsotti C; Tana R; Fanucchi A; Orlandini C; Fabrini MG; Genazzani AR
    Anticancer Res; 2010 Jan; 30(1):201-8. PubMed ID: 20150636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of nodal status and treatment strategy on overall survival in advanced stage cervical cancer.
    Papathemelis T; Knobloch S; Gerken M; Scharl A; Anapolski M; Ignatov A; Inwald EC; Ortmann O; Scharl S; Klinkhammer-Schalke M
    J Cancer Res Clin Oncol; 2019 May; 145(5):1369-1376. PubMed ID: 30887156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concurrent chemoradiotherapy incorporating high-dose rate brachytherapy for locally advanced cervical carcinoma: survival outcomes, patterns of failure, and prognostic factors.
    Teh J; Yap SP; Tham I; Sethi VK; Chua EJ; Yeo R; Ho TH; Tay EH; Chia YN; Soh LT; Khoo-Tan HS
    Int J Gynecol Cancer; 2010 Apr; 20(3):428-33. PubMed ID: 20375809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors and treatment comparison in small cell neuroendocrine cervical carcinoma.
    Yin ZM; Yu AJ; Wu MJ; Zhu JQ; Zhang X; Chen JH; Yuan SH; Yu H
    Eur J Gynaecol Oncol; 2014; 35(3):259-63. PubMed ID: 24984537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of the New FIGO Classification for Cervical Cancer on Patient Survival: A Retrospective Analysis of 265 Histologically Confirmed Cases with FIGO Stages IA to IIB.
    de Gregorio A; Widschwendter P; Ebner F; Friedl TWP; Huober J; Janni W; de Gregorio N
    Oncology; 2020; 98(2):91-97. PubMed ID: 31593942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment outcomes in patients with FIGO stage IB-IIA cervical cancer and a focally disrupted cervical stromal ring on magnetic resonance imaging: A propensity score matching study.
    Kong TW; Lee JD; Son JH; Paek J; Chun M; Chang SJ; Ryu HS
    Gynecol Oncol; 2016 Oct; 143(1):77-82. PubMed ID: 27423377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A study of treatments and outcomes in elderly women with cervical cancer.
    Shimamoto K; Saito T; Kitade S; Tomita Y; Nagayama R; Yamaguchi S; Ariyoshi K; Okadome M
    Eur J Obstet Gynecol Reprod Biol; 2018 Sep; 228():174-179. PubMed ID: 29960201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of local treatment modalities for FIGO stage IB-IIB cervical cancer: A propensity-score matched analysis based on SEER database.
    Song X; Han Y; Shao Y; Gu W; Pei H; Jiang J
    Sci Rep; 2017 Jun; 7(1):3175. PubMed ID: 28600535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of prognostic variables, development of predictive models, and stratification of risk groups in surgically treated FIGO early-stage (IA-IIA) carcinoma cervix.
    Singh P; Tripcony L; Nicklin J
    Int J Gynecol Cancer; 2012 Jan; 22(1):115-22. PubMed ID: 21997176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.